Published in Am J Gastroenterol on August 25, 2015
Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome. Am J Gastroenterol (2016) 1.04
"Gährungsdyspepsie" Revisited. Am J Gastroenterol (2016) 0.85
Intraluminal pH As a Pathophysiological Biomarker of Fermentation in Irritable Bowel Syndrome. Am J Gastroenterol (2016) 0.83
Logical hypothesis: Low FODMAP diet to prevent diverticulitis. World J Gastrointest Pharmacol Ther (2016) 0.77
Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol (2016) 0.77
Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol (2016) 0.76
Response to Valeur et al. and Farmer et al. Am J Gastroenterol (2016) 0.75
Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World J Gastroenterol (2016) 0.75
Meat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures? Int J Tryptophan Res (2017) 0.75
Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation. PLoS One (2017) 0.75
Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol (1997) 8.81
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology (2013) 8.37
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol (2006) 6.09
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol (2000) 5.72
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil (2009) 4.28
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2003) 3.84
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2012) 3.40
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut (1988) 3.14
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol (2000) 2.95
Absorption of short-chain fatty acids by the colon. Gastroenterology (1980) 2.92
Short chain fatty acid absorption by the human large intestine. Gut (1978) 2.87
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
Abnormal colonic fermentation in irritable bowel syndrome. Lancet (1998) 1.91
Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci (2002) 1.90
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil (2012) 1.87
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.73
Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol (2009) 1.73
Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil (2011) 1.72
pH profile of gut as measured by radiotelemetry capsule. Br Med J (1972) 1.60
The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology (2006) 1.54
Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr (2012) 1.51
Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2011) 1.49
Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol (2003) 1.49
Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther (2012) 1.48
Short chain fatty acids and their receptors: new metabolic targets. Transl Res (2012) 1.31
Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil (2010) 1.29
Short-chain fatty acids stimulate motility of the canine ileum. Am J Physiol (1987) 1.27
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci (2007) 1.26
Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil (2011) 1.23
Design of treatment trials for functional gastrointestinal disorders. Gut (1999) 1.23
Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol (2011) 1.21
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
Accurate localization of a fall in pH within the ileocecal region: validation using a dual-scintigraphic technique. Am J Physiol Gastrointest Liver Physiol (2010) 1.15
Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr (1996) 1.14
Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci (2007) 1.07
Role of alimentation in irritable bowel syndrome. Digestion (2003) 1.02
Effect of short-chaim fatty acid on sodium absorption in isolated human colon perfused through the vascular bed. Dig Dis Sci (1981) 1.00
Fiber and functional gastrointestinal disorders. Am J Gastroenterol (2013) 1.00
Degradation of wheat straw by Fibrobacter succinogenes S85: a liquid- and solid-state nuclear magnetic resonance study. Appl Environ Microbiol (2005) 0.88
Assessment of metabolic diversity within the intestinal microbiota from healthy humans using combined molecular and cultural approaches. FEMS Microbiol Ecol (2008) 0.88
Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. Scand J Gastroenterol (1985) 0.85
Response to Valeur et al. and Farmer et al. Am J Gastroenterol (2016) 0.75